Three to six months after COVID-19 disease unstimulated eosinophils still had a lowered expression of CD62L [median MFI, 21 x 104 (IQR 18 x 104-25 x 104) vs. 26 x 104 (IQR 22 x 104-30 x 104), p = 0.0148] and a lower percentage of CD62Lbright cells [median percentage, 70.7% (IQR 63.12–78.8%) vs. 80.1% (IQR 71.3–87.4%), p = 0.0099, Figure 6] when compared to healthy controls. Here, SELL is linked to COVID-19.